The companion animal arthritis pain management market offers a wide range of products including nutraceuticals, drugs, and medical devices for the treatment and management of joint issues in pets. Joint pain is common in older pets as worn joints and painful arthritis take a toll on the mobility and quality of life of pets. The demand for effective and safe pain relief options is increasing due to the rising adoption of pets and growing awareness about animal health issues. Nutraceuticals such as Omega-3 fatty acids and glucosamine supplements are commonly used to manage mild to moderate joint issues in pets. For severe cases, prescription medications like NSAIDs, corticosteroids, and disease-modifying osteoarthritis drugs are used. Medical devices for hydrotherapy and physical therapy are also available for arthritis pet care. The Global companion animal arthritis market is estimated to be valued at US$ 3.83 BN in 2024 and is expected to exhibit a CAGR of 7.4% over the forecast period 2024 to 2031.
Key Takeaways
Key players operating in the companion animal arthritis market are Vetoquinol, NexGen Pharmaceuticals, Norbrook, Eltech K-Laser s.r.l, Zoetis, Virbac, Elanco, Boehringer Ingelheim International GmbH, Ceva, and Dechra Pharmaceuticals PLC. These players are focusing on expanding their product portfolios by developing new drugs and medical devices with minimum side-effects.
The growing pet population worldwide and rising pet ownership are fueling the demand for pet healthcare products and services. According to some estimates, the number of pet dogs adopted in the U.S. itself has increased by over 15 million from 2010 to 2020.
Rapid urbanization and nuclear families have further led to higher pet adoption. The availability of new diagnostic techniques and treatment options is making pet owners more aware of arthritis management. 3D printing technologies are enabling customized medical devices like joint replacements for pets.
Market Trends
Joint health supplements containing chondroitin, glucosamine, and Omega-3 fatty acids are rapidly growing in popularity for arthritis pain relief in pets. These nutraceuticals are preferred first line treatment for mild joint issues.Prescription drugs are also witnessing innovations – sustained release formulations, transdermal gels and wearable patches are expanding treatment options. Regenerative therapies using stem cells and growth factors hold promise to potentially reverse arthritis damage in future.
Market Opportunities
Personalized treatment approaches combining nutraceuticals, drugs, assistive devices, hydrotherapy and physical therapy can better manage pet joint disorders. Telehealth is an emerging opportunity for arthritis consultants to remotely monitor pets and offer treatment advice. Wearable tech linking activity trackers to apps and veterinary portals allows more proactive healthcare. The market remains under-penetrated in developing nations, opening opportunities there. Educating pet owners about early arthritis signs and preventive healthcare can aid timely treatment and management.
Impact of COVID-19 on Companion Animal Arthritis Market
The COVID-19 pandemic has impacted the growth of the Companion Animal Arthritis Market Size. In the initial phases of lockdowns imposed due to the pandemic, veterinary clinics observed a decline in patient footfall. This was majorly due to travel restrictions and people prioritizing essential services only. This affected the diagnosis and treatment of arthritis cases among companion animals. However, with increasing awareness and emphasis on the importance of pet health, owners started getting their pets treated online via teleconsultations. Companies also focused on online channels and home delivery options to ensure continuous availability of arthritis medications. With resumption of regular activities and lifting of lockdowns in most regions, the market is recovering gradually as veterinary facilities are experiencing an increase in patient numbers. Going forward, the demand is expected to grow steadily as owners pay more attention to arthritis management in pets to improve their quality of life.
North America Region
In terms of value, North America has been leading the companion animal arthritis market owing to rising pet ownership and expenditure on animal health in countries like the United States and Canada. As per statistics, over 70% of households own pets and spend significantly on diagnosis and treatment. Moreover, awareness about arthritis and its medications is prominent as most veterinarians actively recommend anti-inflammatory medication and joint supplements for senior pets. The rise in nuclear families and elderly population preferring pet companionship augments the adoption of arthritis medications.
Asia Pacific Region
The Asia Pacific region is poised to witness the fastest growth in the companion animal arthritis market over the forecast period. This is attributed to increasing pet care spending, growing pet population and changing perceptions in developing countries like India and China. As more nuclear families adopt pets, the demand for arthritis drugs and supplements is expected to surge as pet humanization rises. Moreover, veterinary infrastructure is strengthening in Asia with number of clinics, specialty hospitals and e-pharmacies boosting access to arthritis management options. Urbanization and rising disposable incomes will further propel the growth potential across Asia Pacific.
Explore more information on this topic, Please visit –Â
https://www.marketwebjournal.com/companion-animal-arthritis-market-demand-and-outlook-analysis/Â
Explore more trending article –Â
https://www.ukwebwire.com/cancer-biomarkers-market-size-and-tredns-analysis/Â
